📎 AI Summary:
The thread discusses early results from a Phase One human trial of an experimental Ebola vaccine, focusing on whether it appears safe and whether volunteers produced antibodies. The key takeaway is that none of the 20 volunteers experienced major side effects and all generated an immune response, which NIH researchers described as a promising “unqualified success” for early testing. Overall sentiment is cautiously optimistic, with participants treating the trial’s safety and immunogenicity results as encouraging progress.
whoosh

whoosh

Cooler King
Staff member
Member details
Joined
Apr 15, 2009
Messages
48,248
Thread Author #1
The first human trial of an experimental vaccine against Ebola suggests that it is safe and may help the immune system to combat the virus.
Twenty volunteers were immunised in the United States. Scientists at the US National Institutes of Health (NIH) described the results as "promising".
The research is published in the Link Removed (NEJM).
None of those immunised suffered major side-effects and all produced antibodies.
Dr Anthony Fauci of the NIH told the BBC: "On safety and on the ability to produce an appropriate immune response we can call this trial an unqualified success, even though it was an early Phase One trial."
http://www.bbc.co.uk/news/health-30217573 :up: :zoned:
 

You must log in or register to reply here.